The Avoiding Cardiovascular events through COMbination therapy in Patients LIving with
Systolic Hypertension (ACCOMPLISH) trial was the first trial to compare the cardiovascular …

Chronic heart failure (CHF) is common, and increases in incidence and prevalence with
age. There are compelling data demonstrating reduced mortality and hospitalizations with …

Antiarrhythmic drug therapy, broadly defined, is the mainstay of treatment and prevention of
ventricular tachycardia (VT)/ventricular fibrillation (VF), which can lead to sudden death. This …

Background: An angiotensin II type 1 receptor blocker (ARB), telmisartan, has the unique
property of activation of PPAR-γ. Objective: This review aims to discuss clinical perspective …

Heart failure caused by systolic dysfunction affects more than 5 million adults in the United
States and is a common source of outpatient visits to primary care physicians. Mortality rates …

Background and objective Angiotensin II type 1 receptor (AT 1 R) blockade reduces vascular
oxidative stress but whether myocardial oxidative stress represents a mechanism for the …

This article begins with a brief overview of the therapeutic agents used in the treatment of
heart failure, with a special emphasis on pharmacologic agents that block the renin …

Type 2 diabetes is reaching epidemic proportions throughout the world, which has major
health implications as such patients have considerably increased risk of coronary heart …

Ингибиторы АПФ по-прежнему остаются средством выбора для лечения больных ХСН
и систолической дисфункцией ЛЖ. Все попытки сместить или потеснить их с этой …

The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in both cardiac and
renal injury. Inhibition of RAAS with either an angiotensin converting enzyme inhibitor (ACE …